Sansero Life Sciences Announces Joint Study With the University of Toronto to Advance Clinical Research of Psychedelic Medications

TORONTO, October 1, 2020 — Sansero Life Sciences, a leader in the development of psilocybin-based medicines, announced today that it has partnered with the University of Toronto to complete a preclinical study on the effects of low-dose psilocybin. The study will bring new scientific understanding to psilocybin metabolism in the mammalian body and how low-dose psilocybin affects mental health conditions such …

CannaGlobal, Sansero Life Sciences and Rise Wellness Complete Merger, Announce Formation of CannaGlobal Wellness

Toronto, September 3, 2020 — CannaGlobal Canada Co. Inc., Sansero Life Sciences Inc., and Rise Wellness this week announced the completion of their amalgamation to form CannaGlobal Wellness, a global psychedelics leader focused on psilocybin and other natural compounds to promote emotional, mental, and physical wellness. Sansero Life Sciences is developing psilocybin-based pharmaceutical products to treat mental health conditions, and Rise Wellness …

CannaGlobal, Sansero Life Sciences and Rise Wellness Merge to Create a New International Psychedelics Company

TORONTO, July 6, 2020 — CannaGlobal, Sansero Life Sciences, and Rise Wellness today announced the creation of CannaGlobal Wellness, a global psychedelics leader focused on psilocybin and other natural compounds to promote emotional, mental, and physical wellness. Leveraging an internationally renowned team with a track record of success, the company will be ideally positioned in the evolving psychedelics industry. Lorne …